![Karl Deres](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Dr. Karl Deres will join BioMedPartners as a new Venture Partner and will support the representation office in Munich.
Dr. Deres is a biochemist with a strong background in the pharmaceutical industry as well as broad operational expertise and experience in the biotech sector.
Dr. Deres worked for more than 15 years for Bayer Schering Pharma and Intervet Schering Plough.
In 2007, he founded DPC Pharma Consulting, an advisory company offering services in the pharmaceutical/biotech industry, including interim management in the fields of business & strategic
corporate development, clinical & regulatory aspects as well as R&D management.
Aktive Positionen von Karl Deres
| Unternehmen | Position | Beginn |
|---|---|---|
BioMedPartners AG
 BioMedPartners AG Investment ManagersFinance BioMedPartners invests in companies located in Switzerland, Germany and neighboring Western Europe. The firm focuses on biotechnology, emerging pharmaceutical, medical technology and other healthcare-related industries such as diagnostics or platform technologies. It participates in seed and early stage capital transactions. It also makes follow-on investments and acts a lead or co-lead investor. | Private Equity Investor | 14.01.2010 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
13
Beziehungen ersten Grades
1
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
BioMedPartners AG
BioMedPartners AG Investment ManagersFinance BioMedPartners invests in companies located in Switzerland, Germany and neighboring Western Europe. The firm focuses on biotechnology, emerging pharmaceutical, medical technology and other healthcare-related industries such as diagnostics or platform technologies. It participates in seed and early stage capital transactions. It also makes follow-on investments and acts a lead or co-lead investor. | Finance |
